Pasithea Therapeutics annual stock-based compensation
2021
2022
2023
2024
2025
Pasithea Therapeutics Stock-Based Compensation Growth & History (KTTA)
Pasithea Therapeutics's stock-based compensation was $297,467 for fiscal 2025.
View full Pasithea Therapeutics company overviewPasithea Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $297,467 | −$476,226 | −61.55% |
| 2024 | 2024-12-31 | $773,693 | $181,424 | +30.63% |
| 2023 | 2023-12-31 | $592,269 | −$242,795 | −29.08% |
| 2022 | 2022-12-31 | $835,064 | $363,814 | +77.20% |
| 2021 | 2021-12-31 | $471,250 | — | — |
Pasithea Therapeutics quarterly stock-based compensation
Q3.21
Q1.22
Q2.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $329,940 | $272,295 | +472.37% |
| Q1 2026 | 2026-03-31 | $139,182 | $40,624 | +41.22% |
| Q4 2025 | 2025-12-31 | $88,277 | −$30,106 | −25.43% |
| Q3 2025 | 2025-09-30 | $52,987 | −$94,894 | −64.17% |
| Q2 2025 | 2025-06-30 | $57,645 | −$103,307 | −64.18% |
| Q1 2025 | 2025-03-31 | $98,558 | −$247,919 | −71.55% |
| Q4 2024 | 2024-12-31 | $118,383 | $48,443 | +69.26% |
| Q3 2024 | 2024-09-30 | $147,881 | $21,207 | +16.74% |
| Q2 2024 | 2024-06-30 | $160,952 | −$57,682 | −26.38% |
| Q1 2024 | 2024-03-31 | $346,477 | $169,456 | +95.73% |
| Q4 2023 | 2023-12-31 | $69,940 | — | — |
| Q3 2023 | 2023-09-30 | $126,674 | — | — |
| Q2 2023 | 2023-06-30 | $218,634 | −$340,693 | −60.91% |
| Q1 2023 | 2023-03-31 | $177,021 | $41,391 | +30.52% |
| Q2 2022 | 2022-06-30 | $559,327 | — | — |
| Q1 2022 | 2022-03-31 | $135,630 | — | — |
| Q3 2021 | 2021-09-30 | $15,000 | — | — |
Pasithea Therapeutics stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Pasithea Therapeutics's stock-based compensation decreased from $471,250 to $297,467, a change of −$173,783. The latest reported quarter, Q2 2026, shows $329,940.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pasithea Therapeutics source filings ↗